4
Changes in Ownership
Avalo Therapeutics, Inc. Filed Acc 0002013869-25-000002
Director sold 11,367 shares at an average $14.33 ($162,937)
- Director acquired 8,200 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Goldman Jonathan Director | 2025-11-14 | Sale | −3,167 | $14.30 | $45,288 | 0 | D |
| Goldman Jonathan Director | 2025-11-14 | Option exercise | +8,200 | $9.88 | $81,016 | 8,200 | D |
| Goldman Jonathan Director | 2025-11-14 | Sale | −8,200 | $14.35 | $117,649 | 0 | D |
| Derivatives | |||||||
| Goldman Jonathan Director | 2025-11-14 | Option exercise · Stock Option (Right to Buy) | −8,200 | 16,400 | D | ||
| Open-market sales · 11,367 sh · avg $14.33 · $162,937 | |||||||
Loading xslF345X05/primary_doc.xml…